Telephone sharing button Contact Us linkedin sharing button Share wechat sharing button Share wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi Congratulates TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from U.S. FDA
Oct. 23, 2014
WuXi Congratulates TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from U.S. FDA

SHANGHAI, Oct. 23, 2014 — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today congratulates its partner TaiMed Biologics for receiving the Orphan Drug Designation from U.S. FDA for ibalizumab, a humanized monoclonal antibody for the treatment of HIV/AIDS infection. This is a significant milestone that brings ibalizumab one step closer to patients.


“We commend TaiMed’s great progress in advancing this important life-saving therapy,” said Dr. Ge Li, Chairman and CEO of WuXi. “This is the first biologic manufactured in China to receive Orphan Drug Designation, a historic milestone for TaiMed, for WuXi, and also for China.”

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?